Blue Water Biotech, Inc. (NASDAQ: BWV) shares are ripping higher on Wednesday after the company announced the acquisition of six FDA-approved drugs across various treatment areas.
The Details:
Sale aligns with previous plan to separate the company and creates two separate highly focused businessesTransaction valued at approximately 5x enterprise value to Sporting Products Fiscal Year 2024 EBITDA, including
RxSight (NASDAQ:RXST) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.69) by 27.54 percent. This is a 84.57 percent increase over losses of $(3.24) per share from the same
Cryptocurrency influencer and analyst Lark Davis recently shared his thoughts on the current state of the Bitcoin (CRYPTO: BTC) market, indicating the bull run is far from over.